BRAIN POTENTIAL CHANGES AFTER INTRANASAL VS INTRAVENOUS ADMINISTRATION OF VASOPRESSIN - EVIDENCE FOR A DIRECT NOSE BRAIN PATHWAY FOR PEPTIDE EFFECTS IN HUMANS
R. Pietrowsky et al., BRAIN POTENTIAL CHANGES AFTER INTRANASAL VS INTRAVENOUS ADMINISTRATION OF VASOPRESSIN - EVIDENCE FOR A DIRECT NOSE BRAIN PATHWAY FOR PEPTIDE EFFECTS IN HUMANS, Biological psychiatry, 39(5), 1996, pp. 332-340
There is evidence that intranasal application of peptides is a way to
circumvent the blood-brain barrier, This led us to compare the effects
of arginine-vasopressin (AVP) on event-related potentials (ERPs) in h
ealthy men (n = 15) after intranasal and after intravenous (IV) admini
stration. In a double-blind, crossover study, subjects received on thr
ee different occasions 20 IU of AVP intranasally (IN), 1.5 IU of AVP I
V, and saline solution, ERPs were recorded during the subject's perfor
mance on an auditory attention task. Plasma concentrations of vasopres
sin during task performance were enhanced after AVP, with the increase
after IV administration of AVP exceeding that after intranasal AVP (p
< 0.05). Intranasal administration of AVP substantially increased the
P3 component of the ERP (p < 0.01), By contrast, IV administration of
AVP had no consistent effects on the ERP responses. In supplementary
experiments as well, IV administration of lower doses of AVP (0.1 and
0.025 IU) did not affect the ERP. Plasma vasopressin concentrations af
ter the 0.025 IU dose in these experiments were comparable to those af
ter intranasal administration of 20 IU AVP. The results provide functi
onal evidence that in the human brain effects of peptides like AVP may
be facilitated after IN as compared to IV administration.